Episode 66: Scribe Therapeutics

In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than accepting the size, delivery, and precision limitations of traditional Cas9, Scribe is redesigning the molecular machinery itself, building smaller, faster, and more versatile X-Editors and pioneering the future of epigenetic regulation.

We'll dive into the origins of CRISPR from bacterial immune systems to Nobel-winning breakthroughs, the protein engineering philosophy of co-founder Jennifer Doudna and Benjamin Oakes, and why pharmaceutical giants like Biogen, Eli Lilly, and Sanofi have poured resources into its platform. We'll also break down its pipeline targeting cardiometabolic diseases, rare genetic disorders, and the promise of reversible gene silencing.

Because the next era of genetic medicine won't just belong to those who discover biology, but to those who engineer it into safer, more precise cures.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #ScribeTherapeutics #Biotech #CRISPR #GeneEditing #ProteinEngineering #Genomics #Genetics #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Cardiometabolic #Epigenetics #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

As researchers began moving CRISPR from laboratory experiments into human clinical trials, they encountered a new set of challenges. Gene editing wasn't simply about finding the right DNA sequence to cut—it was about ensuring the molecular scissors cut only where they were supposed to. The first generation of CRISPR technologies proved that gene editing was possible. The next generation would have to prove that it could become routine medicine.

Today's story is about one company that believes the future of genome editing won't belong to those who simply discovered CRISPR—but to those who engineer it into something fundamentally better.

That company is Scribe Therapeutics.

Founded by Nobel Prize-winning scientist Jennifer Doudna and a team of protein engineers, Scribe is attempting something remarkably ambitious. Rather than accepting CRISPR's limitations, they're redesigning the molecular machinery itself—building smaller, faster, more precise editing systems capable of reaching tissues and diseases that first-generation editors simply couldn't.

Fresh off one of biotechnology's most anticipated IPOs, Scribe has positioned itself at the center of what many scientists now call CRISPR 2.0. But to appreciate why this company matters, we first need to travel back more than thirty years to a discovery that, at the time, nobody believed would change medicine forever.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Scientific Background: From Curious DNA Repeats to the Biggest Discovery in Modern Biology

Like many revolutionary discoveries, CRISPR began almost by accident.

In 1987, Japanese scientist Yoshizumi Ishino was studying genes involved in phosphate metabolism in Escherichia coli. While sequencing bacterial DNA, his team noticed something peculiar: unusual repetitive sequences separated by unique spacer regions. The finding seemed biologically insignificant, and the team published it almost as an afterthought. For years, virtually nobody knew what those mysterious repeating DNA segments actually did.

Throughout the 1990s, microbiologists began finding similar repetitive patterns across dozens of bacterial species. Eventually, Dutch researcher Ruud Jansen coined the term CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats. Even then, their purpose remained elusive. Some speculated they were evolutionary artifacts. Others thought they helped organize bacterial chromosomes. No one imagined they represented one of nature's most sophisticated immune systems.

The breakthrough came in the early 2000s when several independent groups realized something extraordinary. The spacer sequences sitting between CRISPR repeats perfectly matched fragments of viral DNA. Bacteria, it turned out, were keeping molecular mugshots of viruses they had survived. When those viruses attacked again, CRISPR-associated proteins—Cas proteins—used those stored sequences as guides to recognize and destroy invading viral genomes.

In other words, bacteria had evolved programmable immunity billions of years before humans even understood genetics.

It was an elegant solution. Instead of relying on antibodies like mammals, bacteria stored genetic memories of past infections directly within their DNA. Every future attack triggered an RNA-guided defense system capable of identifying and cutting foreign genetic material with remarkable specificity.

Nature had already invented programmable gene editing.

Scientists simply hadn't recognized it yet.

Jennifer Doudna, Emmanuelle Charpentier, and the Birth of Gene Editing

While microbiologists unraveled CRISPR's biological function, another scientist was becoming fascinated by the strange world of RNA.

Jennifer Doudna grew up in Hawaii, where curiosity about nature shaped much of her childhood. Encouraged by parents who valued education, she developed an early fascination with chemistry and molecular biology after reading The Double Helix, James Watson's famous account of discovering DNA's structure. She would later earn her PhD from Harvard before building an internationally recognized career studying RNA structure and function at Yale and eventually the University of California, Berkeley.

Across the Atlantic, French microbiologist Emmanuelle Charpentier was independently studying bacterial pathogens and their immune systems. Whereas Doudna approached biology from the perspective of structural biochemistry, Charpentier specialized in bacterial genetics. Their expertise perfectly complemented one another.

The two first met at a scientific conference in Puerto Rico in 2011. Their initial conversation reportedly lasted only a short time, but both recognized that combining their expertise could unlock something extraordinary. Within months, they launched a collaboration focused on one particular CRISPR-associated protein: Cas9.

In 2012, their landmark paper demonstrated something that forever changed biotechnology. They showed that Cas9 could be reprogrammed using a synthetic guide RNA to cut virtually any DNA sequence researchers desired.

Instead of engineering a different protein for every gene, scientists simply needed to redesign the guide RNA.

Gene editing had suddenly become programmable.

The publication triggered an explosion across academic biology and venture capital alike. Laboratories around the world immediately began adapting CRISPR for plants, animals, and eventually humans. By 2020, Doudna and Charpentier were awarded the Nobel Prize in Chemistry, becoming the first all-female team ever to receive the award.

Yet even as the world celebrated CRISPR, Doudna remained remarkably cautious.

She often reminded audiences that discovering a technology and safely deploying it were two entirely different challenges.

That realization would eventually lead to the founding of Scribe Therapeutics.

The First Generation of CRISPR Companies

Beneath the optimism, engineers began recognizing important limitations.

Cas9, the workhorse enzyme of first-generation CRISPR, was relatively large, making it difficult to package into commonly used viral vectors such as adeno-associated virus, or AAV. Its size limited which tissues researchers could realistically target.

Scientists also observed varying levels of off-target editing, where DNA sequences resembling the intended target could occasionally be modified unintentionally. While off-target activity could often be minimized through improved guide RNA design, achieving the level of precision required for widespread clinical use remained challenging.

Finally, there was efficiency. Not every cell receiving CRISPR actually underwent successful editing, particularly in tissues beyond the liver and blood.

The field had proven gene editing was possible.

Now it needed better molecular tools.

That realization gave birth to a new generation of companies focused not on discovering CRISPR—but on engineering it.

One of those companies would be founded by the very scientist who helped discover programmable gene editing in the first place.

And instead of asking, "How do we use Cas9?"

They asked a far more ambitious question.

"What if Cas9 isn't the best editor nature has to offer?"

The Founding Story: Jennifer Doudna, Benjamin Oakes, and Reinventing CRISPR

Scribe Therapeutics officially launched in 2018, but the company's origins began years earlier inside Jennifer Doudna's laboratory at the University of California, Berkeley. While much of the biotechnology industry raced to commercialize the original CRISPR-Cas9 system, Doudna and her colleagues had already begun asking an uncomfortable question: what if the first generation of CRISPR tools wasn't good enough for medicine? The technology had proven revolutionary in research laboratories, but therapeutic development demanded a much higher standard. Physicians could tolerate almost no off-target edits, delivery had to become dramatically more efficient, and editing systems needed to fit inside delivery vehicles capable of reaching tissues beyond blood cells and the liver. Solving those problems would require more than incremental improvements—it would require redesigning CRISPR itself.

One of the scientists leading that effort was Dr. Benjamin Oakes, a protein engineer who completed his doctoral work in Jennifer Doudna's laboratory. Unlike many molecular biologists who focused primarily on discovering new CRISPR enzymes, Oakes specialized in understanding how protein structure could be manipulated to improve enzyme function. His work centered on engineering Cas proteins to become smaller, faster, more accurate, and easier to deliver therapeutically. Rather than treating nature's enzymes as finished products, Oakes viewed them as blueprints that could be optimized through modern protein engineering.

Jennifer Doudna had already helped transform biology once through the discovery of programmable gene editing, but she recognized that commercialization required a different skill set. Alongside Oakes and an experienced team of scientists, entrepreneurs, and biotechnology executives, Scribe Therapeutics was founded with a remarkably ambitious mission: to build an entirely new generation of gene-editing tools engineered specifically for human therapeutics. Rather than competing head-to-head using conventional Cas9 systems, Scribe would become an engineering company, redesigning CRISPR from the ground up.

This philosophy differentiated Scribe from many of the first-generation CRISPR companies. Editas, Intellia, and CRISPR Therapeutics largely focused on applying existing editing systems to different diseases. Scribe instead asked whether the editing machinery itself could become dramatically better. It was a subtle but profound distinction. They weren't merely developing drugs—they were developing the tools that future drugs would be built upon.

The Science: Why CasX Could Represent CRISPR 2.0

One of Scribe's earliest breakthroughs came from studying a relatively obscure CRISPR enzyme known as CasX, now more formally called Cas12e. Unlike Cas9, which had become the workhorse of gene editing, CasX originated from bacteria that were evolutionarily distant and structurally distinct. At first glance, it seemed like just another member of the CRISPR family. But closer examination revealed several characteristics that immediately attracted Scribe's scientists.

Most importantly, CasX was significantly smaller than Cas9. Size matters enormously in gene therapy because therapeutic editors must be packaged inside delivery systems. The most commonly used viral vector, adeno-associated virus—or AAV—has an extremely limited carrying capacity. Traditional Cas9 often leaves very little room for guide RNAs, regulatory sequences, or additional genetic cargo. Smaller enzymes open entirely new possibilities for delivery into tissues that had previously been difficult to reach.

But size alone wasn't enough. Scribe's scientists used sophisticated protein engineering, computational biology, and directed evolution to redesign CasX into a family of optimized editors known as X-Editors. These engineered proteins demonstrated improved editing efficiency, enhanced specificity, and reduced off-target activity compared with earlier systems. Rather than accepting nature's original enzyme, Scribe systematically modified amino acid sequences to improve the enzyme's performance inside human cells.

This represents a broader shift occurring throughout biotechnology. Increasingly, scientists no longer view biology as something merely to discover. Instead, biology has become something to engineer. Just as software developers optimize computer code, protein engineers now optimize enzymes, antibodies, and molecular machines for entirely new applications. Scribe sits squarely within this new discipline, combining structural biology, artificial intelligence, protein engineering, and genome editing into a single integrated platform.

Another area where Scribe has focused significant attention is epigenome editing. Traditional CRISPR permanently cuts DNA, creating irreversible genetic changes. Epigenetic editing works differently. Instead of changing the DNA sequence itself, engineered proteins activate or suppress gene expression without altering the underlying genetic code. One can think of it as modifying the software controlling a computer rather than replacing the hardware. This opens the possibility of treating diseases through reversible gene regulation, potentially reducing safety concerns associated with permanent edits.

Building the Platform: Beyond a Single Drug

Unlike traditional biotechnology companies that revolve around one or two lead assets, Scribe has deliberately positioned itself as a platform company. The long-term value isn't simply tied to one therapeutic candidate; it's tied to an engine capable of generating dozens of editors optimized for different diseases and delivery systems.

Its platform includes engineered nucleases for permanent editing, epigenetic editors for reversible gene regulation, base-editing technologies, delivery optimization strategies, and sophisticated computational approaches that improve guide RNA design. Each component feeds into the others. Improvements in protein engineering make delivery easier. Better delivery expands the number of treatable diseases. More accurate editors improve safety, which in turn expands clinical applications.

This systems-based approach is one reason large pharmaceutical companies have become interested in collaborating with Scribe. Rather than licensing a single molecule, partners gain access to an evolving technology platform that can be applied across multiple therapeutic areas over many years.

Strategic Collaborations: Validation from Pharma

One of the earliest major validations came from Biogen, which partnered with Scribe to develop CRISPR-based therapies for neurological diseases. Delivering gene-editing technologies into the central nervous system remains one of biotechnology's greatest challenges, and Biogen recognized that improved editing systems could dramatically expand the number of neurological disorders amenable to gene editing.

In 2023, Eli Lilly entered into a collaboration focused on applying Scribe's technology to cardiometabolic diseases. Cardiovascular medicine represents one of the largest commercial opportunities in biotechnology, with targets such as PCSK9 and lipoprotein(a) attracting enormous industry interest. Lilly's investment reflected growing confidence that engineered CRISPR systems could eventually compete alongside RNA interference, monoclonal antibodies, and small molecules in chronic cardiovascular disease.

Perhaps the most significant validation arrived through Sanofi. Already a global leader in immunology and rare diseases, Sanofi recognized that next-generation genome editing could become a foundational technology across multiple therapeutic franchises. Their collaboration expanded alongside Scribe's recent IPO, with Sanofi participating through a concurrent private investment that underscored long-term confidence in the platform. Importantly, these partnerships weren't merely sources of funding. They represented endorsements from some of the world's largest pharmaceutical companies that Scribe's engineering-first philosophy could define the next era of gene editing.

Scribe Therapeutics priced its upsized initial public offering at $15.00 per share, with its common stock starting to trade on the Nasdaq Global Market on July 24, 2026, under the ticker symbol SCTX.

The Pipeline: From Cardiovascular Disease to Rare Genetic Disorders

Although much of Scribe's value lies in its platform, the company has steadily advanced programs targeting diseases with significant unmet medical need. One area of intense focus has been cardiovascular disease, where permanent reduction of proteins like PCSK9 or lipoprotein(a) could potentially provide lifelong protection against heart attacks and strokes after a single treatment. Unlike daily statins or twice-yearly antibody injections, one-time gene editing offers the possibility of durable risk reduction over decades.

Scribe is also exploring opportunities in rare genetic diseases where correcting a single pathogenic mutation could dramatically alter the course of disease. Here, the combination of highly precise editors and improved delivery systems becomes especially important, as even small improvements in specificity may translate into substantially better safety profiles for patients receiving permanent genetic therapies.

Longer term, the company's epigenetic editing capabilities may open entirely different therapeutic opportunities. Instead of permanently changing DNA, physicians may one day selectively increase or decrease gene activity to treat complex diseases such as neurodegeneration, autoimmune disorders, or metabolic disease. While these programs remain earlier in development, they illustrate how Scribe's ambitions extend well beyond conventional gene editing.

STX-1150: Designed to epigenetically silence the PCSK9 gene to lower LDL cholesterol without permanent DNA breaks, entering clinical evaluation in mid-2026.

STX-1200: Targets the LPA gene using X-Editor technology to durably reduce lipoprotein(a) for atherosclerotic cardiovascular disease (ASCVD).

STX-1400: Targets the APOC3 gene via epigenetic silencing to lower triglycerides and prevent acute pancreatitis in severe hypertriglyceridemia.

Lessons from Scribe Therapeutics

Scribe offers a few lessons worth sitting with — not just for investors, but for anyone trying to understand where medicine is heading.

The discoverer isn't always the best commercializer — but sometimes they are. Jennifer Doudna is one of the rare exceptions. Most Nobel laureates stay in academia. Doudna didn't just win the prize and move on — she built a company premised on the idea that her own discovery wasn't good enough yet. That kind of intellectual humility, combined with the credibility to attract world-class scientists and billion-dollar partnerships, is extraordinarily rare.

Engineering is eating biology. This is perhaps the single most important trend in biotechnology right now, and Scribe is one of its clearest examples. The first generation of biotech was about discovering what nature had already built. The next generation is about redesigning those things from the ground up. Scribe didn't discover CasX. They took it and made it into something nature never produced. That distinction matters enormously.

Platform companies are harder to build but more defensible when they work. Scribe isn't developing a single drug for a single indication. A single platform improvement — a smaller enzyme, a better delivery system — benefits every program simultaneously. When Biogen, Eli Lilly, and Sanofi sign on as partners, they're not buying one drug. They're buying access to an evolving system. That's a fundamentally more durable business.

Reversibility may be undervalued in gene editing. Most of the field's attention has focused on permanent edits. Scribe's investment in epigenetic editing is a bet that the market will eventually demand something different — the ability to turn genes on or off without altering the underlying DNA, opening diseases to gene therapy that permanent editors can never safely address.

What's Next

Scribe is entering the most consequential phase of its existence. The science has been validated, the partnerships secured, the capital raised. Now the question is whether the engineering translates into medicine.

The most important near-term milestone is clinical data. Scribe has demonstrated that X-Editors outperform first-generation systems in preclinical models — but medicine doesn't run on laboratory results. Human data showing real-world editing efficiency and precision is what the field is waiting for.

On the pipeline side, the cardiovascular programs are worth watching closely. Permanent, single-treatment reduction of PCSK9 or lipoprotein(a) is one of the most commercially compelling opportunities in medicine — but the safety bar for a one-time genetic intervention in millions of relatively healthy patients is extraordinarily high. Getting there first, safely, with compelling durability data would be a landmark achievement.

Longer term, the epigenetic editing programs are the wildcard — and potentially the most exciting piece of what Scribe is building. Reversible gene regulation without permanent DNA changes could expand the addressable patient population for gene therapy by an order of magnitude. The science is earlier, but the opportunity is enormous.

Outro

The history of science rarely moves in straight lines.

CRISPR began as an accident — a curious pattern of repeating sequences that a Japanese scientist noticed almost as an afterthought in 1987. It took two more decades to understand what those sequences did. It took Doudna and Charpentier to transform that understanding into a programmable tool. And it took another generation of engineers to begin asking whether even that remarkable tool was good enough yet.

That's how science actually works. Discovery, then refinement, then engineering, then medicine.

Scribe sits at the front edge of that process — not the discoverers of CRISPR, but the engineers trying to make it worthy of the promises made in its name. To the patients waiting for gene therapies precise enough, small enough, and safe enough to reach diseases that have resisted every other approach.

Discovery gets the Nobel Prize. Engineering gets the clinical trial. But in medicine, it's the clinical trial that actually changes lives.

Whether Scribe becomes one of the defining companies of the next era of genetic medicine is a question only data and time can answer. But the scientists building it have already changed biology once.

It would be a mistake to bet against them doing it again.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

1. https://www.scribetx.com/ 
2. www.wikipedia.org
3. https://endpoints.news/ 
4. https://pitchbook.com/ 
5. https://finance.yahoo.com/ 

© 2026 The Perspective Bureau LLC. All rights reserved.